e roche finance report f hoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sales mchf mchf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant currency average rate year end december core result core ep earning share exclude noncore item global restructuring charge amortisation impairment goodwill intangible asset allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give therefinance brief roche roche group report strong overall result core operating profit grow ahead sale core earning share increase constant exchange rate cer swiss franc strong average rate major currency notably japanese yen dollar negative overall impact income statement cash flow express swiss franc sale group sale increase cer billion swiss franc growth swiss franc term pharmaceutical sale growth cer strong growth establish new oncology product actemraroactemra rheumatoid arthritis lucentis ophthalmology partially offset decrease sale pegasys bonvivaboniva loss evista sale japan diagnostic sale grow cer ahead market professional diagnostic major contributor operating result core operating profit increase cer billion swiss franc growth swiss franc term sale growth cost saving global restructuring plan offset high operating cost investment key market impact price pressure increase competition core operating margin increase percentage point research development expenditure grow cer billion swiss franc core basis drive investment oncology neuroscience therapeutic area rd cost group sale ifrs operating result include noncore item billion swiss franc include billion swiss franc amortisation impairment goodwill intangible asset billion swiss franc income reversal previous property plant equipment impairment nonoperating result net financial expense decrease billion swiss franc billion swiss franc drive low interest expense partially offset high net foreign exchange loss net income ifrs net income increase cer billion swiss franc swiss franc term strong core operating result low financing cost low global restructuring charge core earning share increase constant currency swiss franc cash flow operate free cash flow billion swiss franc cer high operating profit free cash flow billion swiss franc cer high operating free cash flow low interest pay repayment debt ahead schedule note bond issue finance genentech transaction repay end financial position net working capital increase cer high level inventory launch growth key product high safety stock level increase demand key market offset increase payable accrue liability net debt position improve billion swiss franc billion swiss franc credit rating strong moodys standard poor aa shareholder return dividend proposal increase dividend swiss franc share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle current liability operating segment information provision contingent liability net financial expense debt income taxis equity attributable roche shareholder business combination chugai global restructuring plan noncontrolle interest property plant equipment employee benefit goodwill pension postemployment intangible asset benefit inventory equity compensation plan account receivable earning share nonvoting equity marketable security security cash cash equivalent statement cash flow noncurrent asset risk management current asset relate party account payable subsidiary associate noncurrent liability significant accounting policy report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche hol ding ltd basel financial statement note financial statement appropriation available earning report statutory auditor financial statement financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group result show growth core operating activity sale core operating profit constant exchange rate cer sale increase region investment continue develop product pipeline secure future sale growth notably research development increase core basis strong operating performance combine low financing cost result increase core ep constant exchange rate strong operating result evident operate free cash flow increase billion swiss franc sale sale pharmaceutical division rise drive growth oncology portfolio significant growth recently launch medicine establish product key growth driver oncology franchise avastin mabtherarituxan zelboraf make significant contribution sale actemraroactemra lucentis increase key emerge market show growth lead sale growth china diagnostic sale grow consolidate division lead market position major growth area professional diagnostic sale diabetes care decline core operating profit increase pharmaceutical division grow diagnostic pharmaceutical division cost sale grow high sale volume initial cost implement supply chain strategy future growth compliance cost negative exchange rate impact increase marketing distribution cost drive investment expand business emerge market increase patient access medicine research development increase arise mainly oncology neuroscience franchise focus new indication recently launch product development pdl target therapy advancement programme alzheimer disease diagnostic division profitability remain stable increase sale offset high operating cost drive pricing impact growth instrument placement especially high research development cost new medical device tax roche group financial review roche finance report major oneoff impact core result release previously accrue reserve b drug discount program positive impact million swiss franc pharmaceutical sale million swiss franc core operating profit million swiss franc income change group pension plan core operating profit group continue implementation number major restructuring initiative position business future operational closure nutley site announce complete schedule end october pharmaceutical division publish detail investment increase global biologic medicine manufacturing network capacity bulk drug production unit vacaville site california discontinue fully write bring service result reversal previously incur impairment charge million swiss franc diagnostic division continue implementation global programme diabetes care apply science business address long term profitability april group announce applied science business area portfolio product integrate business area diagnostic division overall cost group restructure activity billion swiss franc low compare impairment charge billion swiss franc record goodwill intangible asset notably product intangible pharmaceutical division hepatitis c virus hcv franchise goodwill tissue diagnostic business take growth underlie business increase ifrs net income constant exchange rate operate free cash flow billion swiss franc increase constant exchange rate increase reflect cash generation division partly offset high capital expenditure property plant equipment investment intangible asset free cash flow billion swiss franc higher primarily high operating free cash flow low interest payment group debt continues repay partially offset high annual dividend swiss franc appreciate currency particular japanese yen dollar weaken euro overall impact negative result express swiss franc compare constant exchange rate impact percentage point sale core operating profit core eps exchange rate currency sensitivity give roche finance report roche group financial reviewincome statement change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf disclose note consolidated financial statement discuss income statement restate follow accounting policy change adopt restate result cause reduction net financial income million swiss franc investor update march reconciliation previously publish income statement provide note consolidated financial statement roche group financial review roche finance report sale sale increase constant exchange rate swiss franc dollar billion swiss franc sale pharmaceutical division rise franchise avastin mabtherarituxan actemra roactemra lucentis grow strongly emerge market e sale pharmaceutical grow lead growth china represent division sale diagnostic division record sale billion swiss franc increase constant exchange rate consolidate lead market position major growth area professional diagnostic represent half division sale grow diabete care sale decrease divisional operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase core operating result group core operating profit increase constant exchange rate swiss franc group core operating profit margin improve percentage point sale major oneoff impact core result release sale reserve previously accrue b drug discount program positive impact million swiss franc sale million swiss franc core operating profit income million swiss franc record change group pension plan constant exchange rate effect combine positive margin impact percentage point group percentage point pharmaceutical division percentage point diagnostic division exclude factor core operating profit grow group pharmaceutical division diagnostic division currency translation negative impact percentage point operating result minor currency effect group core operate margin positive effect percentage point pharmaceutical division offset negative effect percentage point diagnostic division roche finance report roche group financial reviewpharmaceutical division division increase core operate profit constant exchange rate drive growth underlie business increase sale cost sale increase high sale volume initial cost implement supply chain strategy future growth compliance cost negative exchange rate impact research development cost increase mainly oncology neuroscience franchise increase general administration cost stable percentage sale diagnostic division core operating profit increase drive growth underlie business increase sale cost sale increase sale growth pricing impact growth instrument placement especially marketing distribution cost decrease result low spending diabete care applied science business lower bad debt expense research development cost increase continue investment nextgeneration platforms general administration cost increase cost new medical device tax ongoing system project increase partly offset income record change group pension plan global restructuring plan group continue implementation major global restructuring plan initiate prior year notably reorganisation research development pharmaceutical division programme address longterm profitability diabetes care applied science business diagnostic additionally income million swiss franc reversal previously incur impairment charge bulk drug production unit vacaville site california global restructuring plan cost incur millions chf diagnostic pharma rd plan total global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include restructuring diabete care apply science business area include closure nutley site associate infrastructure environmental remediation cost include operational excellence programme pharmaceutical diagnostic diagnostic division diabetes care apply science restructuring april group announce applied science business area portfolio product integrate business area diagnostic division streamline decisionmake enhance technology flow research use clinical setting september roche diabetes care announce autonomy speed initiative enable business focus diabetes care specific requirement speed process decisionmake drive efficiency total cost million swiss franc incur mainly headcount reduction itrelate cost site closure cost addition goodwill impairment charge million swiss franc incur writeoff goodwill innovatis life science acquisition apply science business area roche group financial review roche finance report pharmaceutical division research development reorganisation june group announce streamline research development activity pharmaceutical division plan operational closure site nutley new jersey complete schedule end total cost million swiss franc incur cost include additional provision million swiss franc cover site running cost expect divestment impairment million swiss franc carry value nutley site base recent external property market datum cost employeerelate site closure reorganisational matter million swiss franc result environmental investigation show expect cost remediation lower originally expect accordingly environmental provision reduce million swiss franc global restructuring plan october pharmaceutical division announce investment increase global biologic medicine manufacturing network capacity meet rise demand license biologic expect pipeline growth bulk drug production unit vacaville site california discontinue fully write service result income million swiss franc reversal previously incur impairment charge cost million swiss franc incur previously announce operational excellence programme mainly employeerelate site closure cost pharmaceutical division employeerelate site closure cost diagnostic division site burgdorf switzerland graz austria plan total million swiss franc merger acquisition july group acquire control interest constitution medical investors inc cmi private company base massachusetts cmi developer highly innovative hematology testing system design provide fast accurate diagnosis bloodrelate disease helping improve patient care cmi report diagnostic operating segment professional diagnostic business area purchase consideration million dollar cash million dollar contingent consideration arrangement impairment goodwill intangible asset impairment charge goodwill intangible asset million swiss franc million swiss franc incur apply science restructuring initiative describe base late business plan prepare second half goodwill impairment million swiss franc record tissue diagnostic business area diagnostic division main factor leading impairment reduce revenue expectation follow recent change college american pathologist guideline use negative reagent control immunohistochemistry testing reduce volume change reduce reimbursement laboratory addition unrelated global restructure impairment total million swiss franc record pharmaceutical division follow portfolio reassessment hepatitis c virus hcv franchise impairment charge million swiss franc record pharmaceutical division small project detail give note consolidated financial statement pension postemployment benefit operate income million swiss franc record past service cost change group pension plan switzerland united kingdom germany represent onetime impact adjustment pension liability plan change million swiss franc record pharmaceutical division million swiss franc diagnostic division remain million swiss franc income allocate corporate mainly attributable previously divest business addition pension plan offer defer vested member settle define benefit obligation lump sum payment result onetime settlement gain ifrs result million swiss franc detail give note consolidated financial statement roche finance report roche group financial reviewlegal environmental settlement addition reversal environmental remediation cost million swiss francs nutley site mention million swiss franc legal environmental cost record unrelated global restructuring plan include increase million swiss franc estimate remediation cost landfill site near grenzach germany previously manufacturing operation close year ago treasury taxation financing cost billion swiss franc decrease interest expense low constant exchange rate debt repay financial income expense net expense million swiss franc mainly loss follow devaluation venezuelan bolivar foreign exchange hedge cost core tax expense increase billion swiss franc group effective core tax rate stable main factor high percentage core profit contribution come tax jurisdiction relatively high local tax rate average group rate notably offset retrospective reenactment research development tax credit rule january net income earning share ifrs net income dilute eps increase constant exchange rate drive strong operating performance significantly low global restructuring expense low financing cost core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset net income core eps increase drive strong operating performance low financing cost core eps grow exclude positive impact b drug discount program change group pension plan supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result financial position change change mchf mchf chf cer pharmaceuticals net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start year swiss franc appreciate significantly japanese yen slight appreciation dollar brazilian real slight weakening euro effect result negative translation impact balance sheet position december exchange rate give roche group financial review roche finance report pharmaceutical division net work capital increase constant exchange rate mainly drive increase inventory recent upcoming product launch expect high sale demand high level safety stock select product temporary bridging stock result change supply chain strategy trade receivables decrease mainly result continue strong collection offset effect underlie business growth trade payable increase follow initiative improve cash management include extension payment term longterm net operating asset grow mainly increase property plant equipment main factor biologic medicine manufacturing network investment result impairment reversal bulk drug production unit vacaville site previously impair partially offset impairment intangible asset hepatitis c virus hcv franchise diagnostic decrease net working capital drive increase trade payable drive extended payment term increase accrual include employee benefit low level inventory trade receivable stable decrease european market offset increase emerge market notably china long term net operating asset stable increase property plant equipment facility germany instrument placement offset impairment goodwill intangible asset decrease net debt position mainly drive free cash flow billion swiss franc transaction equity hedge group employee stock option programme increase net debt billion swiss franc net pension liability decrease billion swiss franc change discount rate pension plan change refer net tax asset increase mainly defer tax effect equity compensation plan increase increase price underlie equity free cash flow change change mchf mchf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay dividend pay free cash flow group operate free cash flow billion swiss franc increase constant exchange rate increase core operating profit partly offset high capital expenditure property plant equipment investment intangible asset increase net working capital note comment financial position high cash utilisation restructure legal provision noncash item core net income include income change group pension plan free cash flow billion swiss franc increase constant exchange rate higher operating free cash flow low interest payment partly offset high annual dividend payment group refine calculation free cash flow exclude impact employee stock option line peer group detail comparative free cash flow information restate accordingly roche finance report roche group financial reviewpharmaceutical division operating result pharmaceutical division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core eps roche group financial review roche finance report sale overview pharmaceutical division sale therapeutic area change sale sale therapeutic area mchf mchf cer oncology immunology infectious disease ophthalmology neuroscience therapeutic area total sale pharmaceutical division sale increase constant exchange rate growth drive oncology portfolio actemraroactemra lucentis increase offset low sale pegasys loss chugais evista sale follow termination comarketing agreement japan expect decline bonviva boniva sale growth primarily drive franchise avastin mabtherarituxan actemraroactemra lucentis main growth driver represent portfolio generate billion swiss franc additional sale sale benefit release previously accrue reserve b drug discount program million swiss franc half mabtherarituxan oncology demand establish product grow expand use exist indication furthermore growth drive franchise follow additional approval perjeta launch kadcyla europe zelboraf continue significant growth contributor sale immunology increase strong growth actemraroactemra region reflect strong uptake actemra monotherapy treatment growth mabtherarituxan rheumatoid arthritis continue growth ophthalmology lucentis sale benefit approval frequent dose regimen wet agerelate macular degeneration wamd increase sale retinal vein occlusion rvo diabetic macular edema dme geographic datum follow sale table present new organisational structure pharmaceutical division investor update march roche finance report roche group financial reviewproduct sale pharmaceutical division sale change sale sale mchf mchf cer oncology avastin herceptin mabtherarituxan xeloda tarceva zelboraf perjeta kadcyla neutrogin total oncology immunology mabtherarituxan actemraroactemra cellcept xolair pulmozyme total immunology infectious disease pegasys valcytecymevene tamiflu rocephin total infectious disease ophthalmology lucentis total ophthalmology neuroscience madopar total neuroscience therapeutic area activasetnkase neorecormonepogin mircera nutropin bonvivaboniva total therapeutic area total sale total mabtherarituxan sale million swiss franc million swiss franc split oncology immunology franchise previous report total neorecormonepogin sale split renal anemia oncology franchise roche group financial review roche finance report mabtherarituxan change sale sale mchf mchf cer united states europe japan international total sale mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra granulomatosis polyangiitis gpa microscopic polyangiitis mpa global sale growth drive increase use oncology rheumatoid arthritis indication sale growth oncology franchise ra franchise sale grow sale billion swiss franc increase benefit release sale reserve b program exclude impact million swiss franc sale rise sale rise international region growth china increase demand treatment diffuse large bcell lymphoma type nhl herceptin change sale sale mchf mchf cer united states europe japan international total sale perjeta change sale sale mchf mchf cer united states europe japan international total sale kadcyla change sale sale mchf mchf cer united states europe japan international total sale roche finance report roche group financial reviewher franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin sale grow international region exclude release sale reserve million swiss franc b program sale rise growth result increase usage breast gastric cancer international region grow subregion asia grow result breast cancer patient access programme testing initiative sale latin america increase private public sector european sale stable sale japan grow recently launch perjeta kadcyla continue growth driver strong uptake recognise benefit compare treatment regimen total franchise grow avastin change sale sale mchf mchf cer united states europe japan international total sale avastin advance colorectal breast lung kidney ovarian cancer relapse glioblastoma type brain tumour global sale grow mainly increase use establish indication colorectal lung breast cancer new indication ovarian cancer ovarian colorectal cancer indication main driver sale increase europe avastin sale grow result expand use colorectal cancer benefit release b program sale reserve exclude impact million swiss franc sale rise growth international region high sale latin america drive increase use colorectal ovarian cancer indication brazil high sale asia subregion china grow drive colorectal cancer indication growth japan primarily use colorectal breast lung cancer lucentis change sale sale mchf mchf cer united states total sale lucentis wet agerelate macular degeneration wamd macular edema follow retinal vein occlusion rvo diabetic macular edema dme sale grow drive growth rvo dme indication stable market share wamd follow approval give early year frequent dose regimen xeloda change sale sale mchf mchf cer united states europe japan international total sale roche group financial review roche finance report xeloda colorectal stomach breast cancer sale increase growth drive primarily china japan increase penetration adjuvant colon cancer acc metastatic colorectal cancer mcrc sales europe impact price pressure loss exclusivity december tarceva change sale sale mchf mchf cer united states europe japan international total sale tarceva advanced nonsmall cell lung nsclc pancreatic cancer sale rise growth china japan growth result approval penetration firstline epidermal growth factor receptor egfr mutationpositive nsclc indication europe partially compensate decrease patient share secondline nsclc international region growth asia support additional reimbursement approval pegasys change sale sale mchf mchf cer united states europe japan international total sale pegasys hepatitis b c sale decrease mainly europe treatment deferral anticipation expect launch interferonfree combination therapie international region growth asia expand access patient market firstgeneration triple therapy recently launch actemraroactemra change sale sale mchf mchf cer united states europe japan international total sale actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis sale continue grow approve indication region result continue strong uptake monotherapy rheumatoid arthritis sale billion swiss franc increase particularly europe actemraroactemra continue gain market share marketing reimbursement approval additional country continue expand patient access actemraroactemra actemra subcutaneous formulation approve japan march october adult live moderately severely active rheumatoid arthritis roche finance report roche group financial reviewneorecormonepogin change sale sale mchf mchf cer united states europe japan international total sale mircera change sale sale mchf mchf cer united states europe japan international total sale anemia franchise neorecormonepogin mircera anemiarenal anemia decline highly competitive market combine sale roche neorecormon chugais epogin epoetin beta decline sustained decline sale neorecormon epogin partly offset growth sale longeracte erythropoiesisstimulate agent mircera rise million swiss franc growth increase number patient switch start treatment mircera place neorecormonepogin strong contribution high mircera sale come japan cellcept change sale sale mchf mchf cer united states europe japan international total sale cellcept prevention solid organ transplant rejection sale stabilise return growth delay generic competition enter market growth japan offset continue decline europe follow patent expiry continued growth japan reflect position cellcept standard care ahead launch generic available end roche group financial review roche finance report tamiflu change sale sale mchf mchf cer united states europe japan international total sale tamiflu influenza b sale increase offset low sale seasonal pandemic use japan zelboraf change sale sale mchf mchf cer united states europe japan international total sale zelboraf braf mutationpositive metastatic melanoma sale grow region zelboraf approve country receive increase reimbursement coverage zelboraf establish standard care braf mutationpositive metastatic melanoma key market france germany uk pharmaceutical division sale region change sale sale region mchf mchf cer united states europe japan international eemea latin america asiapacific region total sale table geographic sale datum show pharmaceutical division present new organisational structure pharmaceutical division investor update march eastern europe middle east africa roche finance report roche group financial reviewunite state sale grow dollar term exclude impact reserve release b drug discount program lead product oncology medicine mabtherarituxan avastin franchise sale billion swiss franc billion swiss franc billion swiss franc respectively product main growth driver lucentis activasetnkase xolair tamiflu actemraroactemra gazyva receive approval november previously untreated chronic lymphocytic leukemia sale remainder million swiss franc europe sale increase constant exchange rate despite impact pricing pressure growth mainly drive oncology product avastin zelboraf perjeta mabtherarituxan addition continue sale growth actemraroactemra partially offset low neorecormon bonvivaboniva sale japan sale grow japanese yen term result japan impact loss evista sale follow termination comarkete agreement negative impact percentage point sale growth major growth driver avastin sale million swiss franc edirol million swiss franc growth actemraroactemra herceptin mabtherarituxan recently launch perjeta bonvivaboniva international sale increase constant exchange rate drive asiapacific latin america subregion growth asiapacific mainly oncology product especially herceptin avastin mabthera rituxan xeloda china main driver region overall sale growth latin america sale growth drive avastin herceptin actemra despite pricing pressure political uncertainty subregion eemea sale grow underlying growth offset timing delay tender sale sale region negatively impact political instability market pharmaceutical division sale e lead emerge market change sale sale country mchf mchf cer total brazil china india mexico russia south korea turkey total sale total sale e key emerge market grow sale growth lead china substantial contribution brazil growth china reflect effort expand patient access medicine investment strategy expand geographical coverage medical care growth brazil result inclusion key product reimbursement scope public healthcare provision sale decline mexico delay market approval public sector purchase growth turkey result strong sale key oncology product roche group financial review roche finance report operating result pharmaceutical division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income decrease constant exchange rate low income disposal product lower large transaction year increase royalty income japan increase royalty high sale outlicense product humira enbrel partly offset milestone income eylea base effect royalty income million swiss franc receive increase outlicense income mainly outlicense agreement japan pharmaceuticals division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis cost sale core cost increase constant exchange rate mainly high sale volume initial cost implement supply chain strategy future growth compliance cost negative exchange rate impact percentage sale cost sale increase slightly royalty expense higher drive newly launch oncology product increase sale avastin tamiflu addition royalty expense million swiss franc late development sanofi arbitration note consolidated financial statement expense collaboration profitshare agreement increase mainly drive high copromotion expense result high sale mabtherarituxan include related release b program sale reserve increase sale xolair tarceva net income global restructuring plan million swiss franc reversal previously incur impairment charge bulk drug production unit vacaville site california note consolidated financial statement pharmaceutical division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan total ifrs basis roche finance report roche group financial reviewmarkete distribution core cost increase constant exchange rate percentage sale ratio improve sale marketing effort focusse continue business expansion increase patient access medicine particular emerge market asia significant investment support exist oncology portfolio newly launch product perjeta kadcyla gazyva pharmaceutical division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis research development core cost increase constant exchange rate percentage sale decrease increase investment oncology neuroscience therapeutic area oncology additional activity focusse new indication recently launch product development pdl target therapy progression programme alzheimer disease main area increase activity neuroscience area partially offset low spend therapeutic area cardiovascular inflammation discontinuation inflammation research nutley addition pharmaceutical division capitalise million swiss franc million swiss franc intangible asset inlicense pipeline compound technology impairment intangible asset include million swiss franc follow portfolio reassessment hepatitis c virus hcv franchise million swiss franc respect project amortisation intangible asset increase recent investment global restructuring cost million swiss franc record consist mainly employeerelate cost outside service closure nutley site pharmaceutical division general administration change mchf mchf cer administration pension past service cost gain loss disposal property plant equipment gain loss divestment subsidiary business taxis capital taxis general item general administration core basis global restructuring plan alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis roche group financial review roche finance report general administration core cost increase constant exchange rate largely stable percentage sale include beneficial impact million swiss franc income change group pension plan increase administration cost mainly result shift finance headcount corporate increase business taxis include cost brand pharmaceutical product fee million swiss franc million swiss franc global restructuring cost mainly include site closure cost nutley consist employeerelate cost property taxis outside service provision million swiss franc cover site running cost expect divestment legal environmental settlement cost mainly relate legal matter describe note consolidated financial statement roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale pharmaceutical division total core operating profit operating profit include elimination million swiss franc million swiss franc unrealise intercompany profit roche pharmaceutical chugai sale core operating profit roche pharmaceutical increase significantly underproportional cost growth marketing distribution research development combine stable general administration cost fall exchange rate japanese yen negative impact approximately chugai result express swiss franc chugais core operating profit increase line increase sale party gross profit sale drive high domestic sale despite loss evista sale income outlicense agreement royalty increase significantly operating expense grow mainly increase rd activity high md spend mainly drive product launch operate free cash flow chugai decrease mainly result net work capital movement significant increase inventory safety stock decrease account payable drive timing material purchase roche pharmaceutical roche finance report roche group financial reviewfinancial position pharmaceutical division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc appreciate significantly japanese yen appreciation dollar brazilian real effect result overall negative translation impact balance sheet position million swiss franc december exchange rate give net work capital increase net trade work capital constant exchange rate increase inventory partly offset reduction trade receivable increase trade payable high level inventory recent upcoming product launch actemraroactemra herceptin subcutaneous sc formulation kadcyla perjeta expect high sale demand establish product increase safety stock select exist product temporary bridging stock result change supply chain strategy trade receivables decrease despite sale increase result continue strong collection notably europe eemea region trade payable increase follow initiative improve cash management include extension payment term decrease net liability receivables payable mainly increase prepay expense royalty receivables longterm net operating asset increase increase property plant equipment low provision partially offset decrease intangible asset movement property plant equipment mainly attributable capital expenditure project describe free cash flow section impairment reversal bulk drug production unit vacaville site intangible asset decrease impairment follow portfolio reassessment hepatitis c virus hcv franchise impairment provision decrease utilisation restructure legal provision addition nutley environmental provision transfer pharmaceutical division corporate manage centrally plan site divestment roche group financial review roche finance report free cash flow pharmaceutical division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide pharmaceutical division operate free cash flow increase constant exchange rate billion swiss franc increase cash generation underlie business represent growth core operating profit partly increase net working capital note comment financial position operating profit net cash adjustment increase adjustment noncash item core result largely offset capital expenditure property plant equipment relate investment efficiency improvement manufacturing facility increase production capacity particular transfer function nutley site location infrastructure expansion result business growth asia increase expenditure site development basel roche finance report roche group financial reviewdiagnostic division operating result diagnostic division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale diagnostic division sale grow ahead global vitro diagnostic market region contribute sale growth constant exchange rate billion swiss franc growth predominantly drive continued strong demand immunoassay platform clinical laboratory roche professional diagnostic business area regionally emerge market diabetes care sale decrease continued market challenge reimbursement change blood glucose monitor key market notably molecular diagnostic grow continue strong uptake hpv test main growth driver blood screen product return growth worldwide growth oncology test nucleic acid purification nap product life sciences tissue diagnostic sale increase market growth region grow low rate reimbursement guideline change roche group financial review roche finance report april group announce applied science business area portfolio product integrate group diagnostic business area polymerase chain reaction technology pcr nucleic acid purification nap biochemical reagent line manage molecular diagnostic custom biotech portfolio move professional diagnostic dedicated unit establish focus solely sequence sale information reclassify retrospectively sale sequence business report result molecular diagnostic total divisional sale unchanged diagnostic division sale business area change sale sale business area mchf mchf cer professional diagnostic diabetes care molecular diagnostic tissue diagnostic total sale professional diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale professional diagnostic sale grow respective market extend roche position market leader strong growth drive immunoassay clinical chemistry business coagulation patient selfmonitore hematology contribute good performance region achieve sale growth asiapacific region main regional growth driver sale small latin america region grow north america sale increase cobas cobas product line automation solution main contributor emea region sale grow mainly immunoassay tests clinical chemistry product coagulation patient selfmonitore business strong growth north america japan sale grow immunoassay business continue growth contribute quarter division total sale test marker oncology thyroid disorder cardiac disease women health include vitamin infectious disease majority immunoassay sale hematology business show strong growth momentum russia latin america key milestone business area launch new cobas instrument fully automate workflow series manage numerous routine laboratory task simplify operation customer reduce manual handling sample increase costefficiencie process urgent sample twice speed early version system system available globally launch achieve good market uptake reorganisation apply science business area custom biotech portfolio professional diagnostic business area reflect comparative information roche finance report roche group financial reviewdiabete care change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale diabetes care decrease sale reflect reimbursement cut blood glucose monitoring supply especially ongoing price pressure key market continue competition lowcost provider sale decrease north america reimbursement cut important segment market business grow asiapacific latin america sales stable emea country affect lowcost provider sale japan low sale accuchek mobile target frequent tester grow sale oldgeneration accu chek compact advantage meter continue decline sale insulin delivery system grow growth blood glucose monitoring bgm strip volume meter placement offset continue price pressure bgm sector total lead decline global sale diabete care business business continue market launch nextgeneration version exist brand accuchek active accuchek avivaperforma meter receive fda clearance accuchek aviva expert system accuchek active meter nextgeneration nocode accuchek avivaperforma meter launch quarter globally nocode accuchek nano smartview meter test strip available roche diabetes care initiate restructure notably research development activity include marketing manufacturing activity sustain longterm profitability restructure step take activity continue molecular diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale molecular diagnostic underlie growth molecular diagnostic business exclude sequence sale main contributor test human papilloma virus hpv nucleic acid purification naprealtime pcr qpcr reagent system life science market product blood screen sale growth report region north america main growth driver hpv test sale blood screen sale blood screening grow asiapacific emea region sale growth napqpcr reagent lead growth sale oncology companion test japan sale grow sale blood screening represent significant proportion business area total sale show return growth second half impact time difference order pattern see half year normalise sale oncology companion diagnostic test area high medical value show significant growth roche group financial review roche finance report follow reorganisation apply science business area realtime pcr technology nap nucleic acid purification portfolio biochemical reagent molecular diagnostic business sale sequence business report result molecular diagnostic change reflect comparative information tissue diagnostic change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale tissue diagnostic sale growth mainly advanced staining reagent business region record sale growth north america sale increase low global growth recent change guideline reimbursement sale growth outside asiapacific report sale growth advance stain notably china australia south korea emea sale increase strong growth reagent sale new primary stain instrument sale sale primary stain strong contribution special stain business revenues external personalise healthcare partner sale companion test continue grow cintec plus cytology test fully automate cellbase assay cervical cancer screening obtain ce mark december base late business plan prepare second half goodwill impairment million swiss franc record tissue diagnostic business diagnostic division main factor leading impairment reduce revenue expectation follow recent change college american pathologist guideline use negative reagent control immunohistochemistry testing reduce volume change reduce reimbursement laboratory diagnostic division sale region change sale sale region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sale divisional sale growth primarily drive asiapacific emea europe middle east africa latin america region demand particularly high china sale rise immunodiagnostic clinical chemistry reagent key growth driver asiapacific region sale growth emea region lead professional diagnostic tissue diagnostic contribute latin america professional diagnostic molecular diagnostic tissue diagnostic show solid growth north america sale grow strong sale growth immunoassay coagulation monitor molecular diagnostic particular hpv blood screen business growth offset sale decline diabetes care significant cut reimbursement immunoassay sale grow large contributor growth japan roche finance report roche group financial reviewdiagnostic division sale e lead emerge market change sale sale country mchf mchf cer brazil china india mexico russia south korea turkey total sale e market contribute sale growth mainly professional tissue diagnostic business area brazil division reinforce market leadership ivd market south korea growth drive commercial laboratory automation project professional tissue diagnostic enhance testing efficiency customer site ongoing focus innovative safe blood testing patient india division double site nucleic acid test nat result growth molecular diagnostic operating result diagnostic division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income decrease constant exchange rate drive low royalty income mainly result royalty payment million swiss franc receive reoccur diagnostic division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis roche group financial review roche finance report cost sale core cost increase constant exchange rate increase manufacturing cost good sell period cost overall growth core cost high sale growth pricing impact growth instrument placement especially increase diabetes meter placement increase partially offset onetime vat refund million swiss franc relate meter placement prior year result cost sale ratio compare global restructuring cost mainly reorganisation apply science business closure site graz austria burgdorf switzerland amortisation product intangible decrease intangible asset fully amortise diagnostic division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis marketing distribution core cost decrease constant exchange rate low spending diabete care apply science business follow restructure initiative bad debt expense low decrease partially offset increase spending sale force distribution professional diagnostic molecular diagnostic asiapacific latin america region marketing distribution cost increase sale force expansion penetrate emerge market offset low spending emea region core basis marketing distribution cost percentage sale compare global restructuring cost mainly reorganisation diabetes care applied science business improve efficiency marketing distribution activity diagnostic division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis research development core cost increase constant exchange rate drive increased spending instrument development cost major platform professional molecular diagnostic furthermore research development cost increase acquisition constitution medical investors inc boston applied science business expense decline significantly result ongoing restructuring diabete care cost remain stable result cost containment programme initiate percentage sale research development core cost increase global restructuring cost mainly relate reorganisation apply science business closure site graz austria intangible asset impairment million swiss franc incur reorganisation roche finance report roche group financial reviewdiagnostics division general administration change mchf mchf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment intangible asset alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis general administration core cost increase constant exchange rate increase administration cost high employee cost professional diagnostic staff global project ramp new develop affiliate increase certain legal cost business taxis increase new medical device tax cost million swiss franc general item include ongoing system project standardise automate centralise business process increase offset income million swiss franc record change group pension plan percentage sale core cost increase global restructuring cost mainly global project employeerelate cost reorganisation apply science business addition goodwill impairment charge million swiss franc record tissue diagnostic business million swiss franc incur writeoff goodwill life science innovatis acquisition applied science business financial position diagnostic division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give roche group financial review roche finance report currency translation effect balance sheet amount compare start year swiss franc appreciate dollar slightly weaken euro effect result overall negative translation impact balance sheet position million swiss franc december diagnostic division significant net asset position japanese yen appreciation swiss franc japanese yen minor impact exchange rate give net work capital net trade work capital decrease drive increase trade payable decrease inventory trade payable increase extend payment term inventory decrease increase inventory provision trade receivables stable high collection partially offset increase follow growth business emerge market notably china increase net liability receivablespayable main factor increase receivablespayable high accrual include employee benefit partially offset increase prepay expense longterm net operating asset remain stable constant exchange rate decrease intangible asset offset increase investment property plant equipment property plant equipment increase high instrument placement site expenditure germany goodwill intangible asset decrease impairment tissue diagnostic apply science business area partially offset acquisition constitution medical investors inc provision decrease net utilisation restructure provision free cash flow diagnostic division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide operate free cash flow diagnostic division increase billion swiss franc cash generation business support decrease net working capital mainly increase payable note comment financial position operating profit net cash adjustment decrease core operating profit increase difference noncash item include income change group pension plan cash utilisation restructure provision low bad debt expense capital expenditure property plant equipment billion swiss franc result investment facility germany instrument placement particularly china germany roche finance report roche group financial reviewcorporate operating result corporate operating result summary change mchf mchf cer administration pension past service cost business taxis capital taxis general item general administration cost core basis global restructuring plan alliance business combination legal environmental settlement pension settlement gain loss total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result core eps general administration core cost decrease constant exchange rate positive impact million swiss franc record change group pension plan mainly attributable previously divest business administration expense decrease mainly shift headcount pharmaceutical division increase general item drive cost relate ongoing system project total cost ifrs basis decrease environmental expense include increase estimate cost remediation landfill site grenzach germany million swiss franc partly offset release million swiss franc environmental remediation provision nutley site corporate operating free cash flow show high outflow reduction account payable notably accrual employee benefit major reason decrease core cost noncash income change group pension plan roche group financial review roche finance report foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer swiss francs change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy compare swiss franc strong currency particular japanese yen dollar weaken notably euro overall impact negative income statement free cash flow result express swiss franc compare constant exchange rate sale development result negative impact percentage point equivalent billion swiss franc translate swiss franc currency translation exposure operating profit mitigate group majority cost base locate outside switzerland sensitivity group sale core operating profit absolute term movement average foreign currency exchange rate swiss franc show table currency sensitivity impact change average exchange rate sale core operating profit versus swiss franc mchf mchf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany obviously large majority chugais cost denominate japanese yen roche finance report roche group financial reviewtreasury taxation result treasury taxation result change change mchf mchf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position treasury taxation net debt pension income taxis financial noncurrent asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury taxation treasury activity taxis pay dividend pay total disclose note consolidated financial statement discuss income statement restate follow accounting policy change adopt restate result cause reduction net financial income million swiss franc investor update march reconciliation previously publish income statement provide note consolidated financial statement page definition core result core ep roche group financial review roche finance report financing cost finance cost million swiss franc decrease million swiss franc compare main driver decrease interest expense reflect continue repayment debt incur finance genentech transaction loss early redemption debt million swiss franc compare million swiss franc net interest cost pension plan remain stable million swiss franc analysis financing cost give note consolidated financial statement financial income expense financial income expense net expense million swiss franc net income equity security million swiss franc increase interest income income debt security decrease million swiss franc shortterm interest rate remain low level major market foreign exchange result mainly reflect hedging cost loss million swiss franc compare loss million swiss franc foreign exchange result include loss million swiss franc follow devaluation venezuelan bolivar february million swiss franc loss hedge group euroswiss franc position analysis financial income expense give note consolidated financial statement detail group hedge arrangement give note income taxis group effective core tax rate stable high percentage core profit contribution come tax jurisdiction relatively high local tax rate average group rate notably increase effective tax rate offset retrospective reenactment research development tax credit january mean result include year tax credit respect tax credit tax benefit million swiss franc record noncore item compare tax benefit million swiss franc decrease primarily lower underlie noncore expense compare specifically global restructuring plan include intangible asset impairment low legal environmental cost detail group income tax position give note consolidated financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate core basis global restructuring plan goodwill intangible asset equity compensation plan group effective tax rate ifrs basis financial position decrease net debt position mainly drive free cash flow billion swiss franc transaction equity hedge group employee stock option programme increase net debt billion swiss franc net pension liability decrease billion swiss franc change discount rate change plan rule group pension plan net tax asset increase mainly defer tax effect equity compensation plan increase increase price underlie equity interest payable relate bond note coupon payment date march september decline continue repayment underlie debt december group hold financial longterm asset market value billion swiss franc consist holding biotechnology company acquire context licensing transaction scientific collaboration roche finance report roche group financial reviewfree cash flow cash outflow treasury activity decrease billion swiss franc low interest payment total taxis pay billion swiss franc increase constant exchange rate high tax payment partially offset base effect settlement certain outstanding tax position total dividend pay billion swiss franc increase billion swiss franc compare reflect increase roche group dividend cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow roche group financial review roche finance report operate free cash flow increase constant exchange rate billion swiss franc drive strong growth underlie operating business core operate profit growth increase net work capital mainly inventory capital expenditure property plant equipment investment intangible asset high division increase cash generate business partly absorb cash utilisation restructure legal provision cash outflow treasury activity decrease billion swiss franc low interest payment total taxis pay billion swiss franc increase constant exchange rate high tax payment partially offset base effect settlement certain outstanding tax position total dividend pay high increase annual roche group dividend free cash flow billion swiss franc high constant exchange rate mainly increase operate free cash flow low interest payment partly offset high dividend payment group refine calculation free cash flow exclude impact employee stock option line peer group detail comparative free cash flow information restate accordingly net debt million chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt period december cash cash equivalent marketable security longterm debt shortterm debt net debt end period roche finance report roche group financial reviewnet debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euros swiss franc pound sterling swap dollar financial statement economic characteristic equivalent dollardenominate bond note net debt position group december billion swiss franc decrease billion swiss franc december decrease net debt mainly free cash flow billion swiss franc describe include dividend payment billion swiss franc transaction equity hedge group employee stock option programme increase net debt billion swiss franc group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk fair value derivative hedging instrument increase strengthen euro dollar cash collateral billion swiss franc receive roche collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro pound sterling currently collateral balance move approximately million dollar foreign exchange rate simultaneously redemption repurchase bond note note consolidated financial statement impact liquid fund impact net debt position detail group marketable security cash debt position give note consolidated financial statement pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource roche group financial review roche finance report define benefit plan expense group define benefit plan million swiss franc million swiss franc decrease mainly past service income million swiss franc settlement income million swiss franc describe partially offset increase current service cost million swiss franc drive low discount rate begin compare beginning expense account implementation ias revise increase net interest cost pension million swiss franc approximately base revise actuarial assumption end expense group define benefit plan expect approximately million swiss franc estimate pension expense include settlement past servicecurtailment effect arise year operate income million swiss franc record past service cost change group pension plan switzerland uk germany represent onetime impact adjustment pension liability plan change million swiss franc record pharmaceutical division million swiss franc diagnostic division remain million swiss franc income allocate corporate mainly attributable previously divest business addition pension plan offer defer vested member settle define benefit obligation lump sum payment total lump sum payment reduce plan asset million swiss franc settle million swiss franc define benefit obligation result gain settlement million swiss franc funding status balance sheet position mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group define benefit plan increase compare start year funding improvement mainly reduction define benefit obligation arise rise discount rate end comparison end change group plan refer decrease define benefit obligation million swiss franc plan asset remain stable company contribution increase million swiss franc compare million swiss franc settlement plan reduce plan asset million swiss franc fund status pension fund monitor local pension fund governance body closely review group level addition cash injection group initiate plan change local pension plan describe detail group pension postemployment benefit give note consolidated financial statement roche finance report roche group financial reviewroche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group swiss franc term constant exchange rate healthcare sector outperform general market despite continue pricing pressure government budget constraint part world roche share outperform healthcare sector company achieve important new product approval kadcyla breast cancer gazyva hematological cancer peer group abbott abbvie amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche sanofi takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index source datastream datum roche peer index rebase january peer index convert chf daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index roche group financial review roche finance report propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting th consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security billion swiss franc billion swiss franc result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page finance report information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note consolidated financial statement finance report payout ratio calculate dividend share divide core earning share payout ratio restate follow accounting policy change adopt roche finance report roche group financial reviewdebt finance genentech transaction group issue bond note equivalent billion swiss franc debt raise early repay december include redemption billion eurodenominate note date march billion dollar note originally march redeem march follow exercise early option december addition million dollar note originally march redeem august follow exercise group early option june second half year group redeem million swiss franc bond date september december group exercise option early redemption billion dollar note march note repay march maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf total total translate december exchange rate follow group exercise early option december billion dollar note originally redeem march year ahead contractual maturity proceed bond note billion euro swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note f proceed bond note million pound sterling swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation free cash flow billion swiss franc include cash generate operation payment interest tax dividend shortterm financing requirement group commercial paper programme issue billion dollar unsecured commercial paper note commit credit line billion euro available backstop line commercial paper note total billion dollar outstanding december billion dollars longerterm financing group maintain strong longterm investmentgrade credit rating aa standard poor moodys facilitate efficient access international capital market credit rating roche group december shortterm longterm outlook moodys p stable standard poor aa stable roche group financial review roche finance report financial risk december group net debt position billion swiss franc billion swiss franc financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security mchf total mchf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group billion swiss franc cash fix income marketable security remain strong invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables billion swiss franc continue financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivable billion euro billion swiss franc public customer country decrease compare december improve collection italy greece portugal spain remain stable compare group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action group apply new commercial arrangement public hospital greece portugal liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year roche strong longterm investmentgrade credit rating aa standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total billion swiss franc billion swiss franc serve backstop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change foreign exchange rate interest rate group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var increase mainly gradual increase longterm interest rate major economy roche finance report roche group financial reviewinter rate risk interest rate risk arise movement interest rate affect group financial result value group equity group hedge management group enter interest rate swap contract combine notional principal billion dollar swap fix interest rate effective float interest rate month usdlibor plus average spread maturity swap march period group enter interest rate swap contract combine notional principal million swiss franc swap fix interest rate effective float interest rate month chflibor plus average spread maturity swap september information financial risk management financial risk var methodology include note consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result new revise standard implement effective january list note consolidated financial statement note material impact group overall result financial position matter revise version ias employee benefit include follow change exist standard e liminating option defer recognition actuarial gain loss define benefit postemployment plan know corridor method group previously apply option use option recognise gain loss comprehensive income option previously apply group henceforth requirement revise standard change impact group financial statement previous method include expect income plan asset estimate asset return replace discount rate discount define benefit obligation restate result cause reduction net financial income million swiss franc impact roche operating income net asset change p ast service cost recognise immediately income statement period plan amendment previously past service cost portion relate unvested benefit defer balance sheet progressively release information topic publish investor update march available httpwwwrochecominvestorsirupdateinvupdatehtm group currently assess potential impact new revise standard interpretation effective january group apply base analysis date group anticipate material impact group overall result financial position roche group financial review roche finance report roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf disclose note income statement year end december restate follow accounting policy change adopt reconciliation previously publish income statement provide note roche group roche group consolidate financial statement roche finance report roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income remeasurement define benefit plan item reclassify income statement availableforsale investment cash flow hedge currency translation foreign operation item reclassified subsequently income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total disclose note statement comprehensive income year end december restate follow accounting policy change adopt reconciliation previously publish statement comprehensive income provide note roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity disclose note balance sheet december december restate follow accounting policy change adopt reconciliation previously publish balance sheet provide note roche group roche group consolidate financial statement roche finance report roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group roche group consolidated financial statementsroche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december disclose note statement change equity year end december restate follow accounting policy change adopt reconciliation previously publish total equity january provide note roche group roche group consolidate financial statement roche finance report note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist multiple component occur different time group party outlicense agreement involve upfront milestone payment occur year involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary roche finance report roche group note roche group consolidated financial statementsat december group million swiss franc provision accrual expect sale return chargeback rebate include medicaid similar rebate country estimate base analyse exist contractual legislatively mandate obligation historical trend group experience december group million swiss franc provision doubtful receivables note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account current economic condition business combination group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest consideration transfer business combination management judgement particularly involve recognition fair value measurement intellectual property contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term impairment december group million swiss franc property plant equipment note million swiss franc goodwill note million swiss franc intangible asset note goodwill intangible asset available use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate discount future cash flow factor change discount rate plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate product sale lead short useful life impairment pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation million swiss franc note actuarial assumption differ materially actual result change market economic condition long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate december group million swiss franc legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress reliable estimate provision record contingent liability disclose material environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group million swiss franc environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contaminate site method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress roche group note roche group consolidate financial statement roche finance report income taxis december group current income tax net liability million swiss franc defer tax net asset million swiss franc note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement transaction structure entity case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term roche finance report roche group note roche group consolidate financial statement operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis pension fund management legal safety environmental service subdivisional information roche pharmaceutical chugai operate segment pharmaceutical division present divisional information million chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense roche group note roche group consolidate financial statement roche finance report pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination profit division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group disclose note nonoperate net asset december december restate follow accounting policy change adopt reconciliation previously publish balance sheet provide note roche finance report roche group note roche group consolidated financial statementsnet operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division information geographical area millions chf revenue external customer noncurrent asset royalty operate property plant goodwill sale income equipment intangible asset switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group note roche group consolidate financial statement roche finance report supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue european union information base members eu december major customer total national wholesale distributor represent approximately quarter group revenue national wholesale distributor amerisourcebergen corp billion swiss franc billion swiss francs mckesson corp billion swiss franc billion swiss franc cardinal health inc billion swiss franc billion swiss franc approximately revenue pharmaceutical operating segment residual diagnostic segment net financial expense financing cost millions chf interest expense amortisation debt discount net gain loss redemption repurchase bond note discount unwind net interest cost define benefit plan total financing cost financial income expense millions chf net gain loss sale equity security net gain loss equity security derivative dividend income writedown impairment equity security net income equity security interest income net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss net financial income expense associate total financial income expense roche finance report roche group note roche group consolidated financial statementsnet financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense disclose note net financial expense year end december restate follow accounting policy change adopt reconciliation previously publish net financial expense provide note income taxis income tax expense millions chf current income taxis defer taxis total income tax expense disclose note income tax expense year end december restate follow accounting policy change adopt reconciliation previously publish income tax expense provide note group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate increase percentage point main driver increase growth proportion group profit generate relatively high local tax rate average group rate significant local tax rate change main operating area group compare group effective tax rate increase main driver increase increase average expect tax rate explain partially offset retrospective reenactment research development tax credit january mean result include year tax credit respect tax credit roche group note roche group consolidate financial statement roche finance report group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development manufacturing tax credit state tax impact tax unremitted earning utilisation previously unrecognise tax loss difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity million swiss franc million swiss franc income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately million swiss franc million swiss franc record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan availableforsale investment cash flow hedge currency translation foreign operation comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liabilitie roche finance report roche group note roche group consolidated financial statementscurrent income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect net current income tax asset liability december defer taxis movement recognise net asset liability millions chf property plant intangible define temporary equipment asset benefit plan difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december defer tax asset temporary difference mainly relate accrue liability provision unrealise profit inventory roche group note roche group consolidate financial statement roche finance report defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable mchf tax rate mchf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable unremitted earning foreign subsidiary amount currently regard permanently reinveste total unremitted earning group regard permanently reinveste billion swiss franc december billion swiss franc business combination acquisition constitution medical investors inc july group acquire control interest constitution medical investors inc cmi private company base massachusetts cmi developer highly innovative hematology testing system design provide fast accurate diagnosis bloodrelate disease helping improve patient care cmi report diagnostic operating segment professional diagnostic business area total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise end range undiscounted outcome zero million dollar identifiable asset acquire liability assume set table acquisition net asset acquire millions chf cmi intangible asset product intangible available use defer tax liability net asset liability net identifiable asset goodwill total consideration cash contingent consideration total consideration roche finance report roche group note roche group consolidated financial statementsthe fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate valuation perform independent valuer goodwill represent control premium synergy obtain group exist business goodwill expect deductible income tax purpose directly attributable transaction cost million swiss franc report diagnostic operating segment general administration expense impact cmi acquisition diagnostic division group report result material acquisition verum january group acquire control interest verum diagnostica gmbh verum german private company base munich verum report diagnostic operating segment total consideration million euro million euro pay cash million euro arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero million euro identifiable asset acquire liability assume set table acquisition net asset acquire millions chf verum intangible asset product intangible use inventory defer tax liability net asset liability net identifiable asset goodwill total consideration cash contingent consideration total consideration cash flow business combination acquisition net cash outflow millions chf cash consideration pay cash acquire company contingent consideration pay total net cash outflow roche group note roche group consolidate financial statement roche finance report global restructuring plan group continue implementation major global restructuring plan initiate prior year notably reorganisation research development pharmaceutical division programme address longterm profitability diabetes care applied science business diagnostic additionally income million swiss franc reversal previously incur impairment charge bulk drug production unit vacaville site california global restructuring plan cost incur millions chf diagnostic pharma rd plan total year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost include restructuring diabete care apply science business area include closure nutley site associate infrastructure environmental remediation cost include operational excellence programme pharmaceutical diagnostic dalcetrapib pharmaceutical diagnostic division diabetes care apply science restructuring april group announce applied science business area portfolio product integrate business area diagnostic division streamline decisionmake enhance technology flow research use clinical setting september roche diabetes care announce autonomy speed initiative enable business focus diabetes care specific requirement speed process decisionmake drive efficiency initiative announce diabete care apply science business include increase efficiency marketing distribution operation research development activity roche finance report roche group note roche group consolidate financial statementsdure total cost million swiss franc million swiss franc incur mainly headcount reduction itrelate cost site closure cost addition goodwill impairment charge million swiss franc incur writeoff goodwill innovatis life science acquisition apply science business area intangible asset impairment charge million swiss franc incur related restructure goodwill impairment charge million swiss franc incur writeoff goodwill nimblegen acquisition intangible asset impairment charge million swiss franc incurred pharmaceutical division research development reorganisation june group announce streamline research development activity pharmaceutical division plan operational closure site nutley new jersey complete schedule end total cost million swiss franc incur cost include million swiss franc employee relate site closure cost year additional provision million swiss franc cover site running cost expect divestment provision mainly employeerelate cost property taxis outside service impairment million swiss franc carry value nutley site base recent external property market datum result environmental investigation show expect cost remediation lower originally expect accordingly environmental provision reduce million swiss franc total cost million swiss franc incur mainly severance employeerelate cost property plant equipment impairment nutley site addition environmental remediation cost nutley site million swiss franc intangible asset impairment charge million swiss franc result portfolio prioritisation decision link reorganisation global restructuring plan october pharmaceutical division announce investment increase global biologic medicine manufacturing network capacity bulk drug production unit vacaville site california discontinue fully write service result income million swiss franc reversal previously incur impairment charge note cost million swiss franc million swiss franc incur previously announce operational excellence programme mainly employeerelate site closure cost pharmaceutical division employeerelate site closure cost diagnostic division site burgdorf switzerland graz austria plan total million swiss franc million swiss franc million swiss franc restructuring cost intangible asset impairment charge million swiss franc respect termination dalcetrapib daloutcome trial study dalheart programme roche group note roche group consolidate financial statement roche finance report global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment reversal property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value roche group note roche group consolidate financial statement roche finance report impairment reversal charge october pharmaceutical division announce detail investment increase global biologic medicine manufacturing network capacity meet rise demand license biologic expect pipeline growth investment spread site penzberg germany basel switzerland vacaville oceanside bulk drug production unit vacaville site california license discontinue fully write reassessment global manufacturing network requirement time bulk drug production unit vacaville site require capital investment operational expect occur group decision restart licensing effort prepare operational use discontinue bulk drug production unit vacaville site commercial manufacturing result impairment reversal property plant equipment million swiss franc impairment reversal million swiss franc represent net book value time original impairment asset bring use depreciation charge intervene period impairment occur note partly offset impairment million swiss franc carry value nutley site base recent external property market datum impairment charge mainly relate property plant equipment nutley site classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment reversal charge reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment lease arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum payment lease payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc roche finance report roche group note roche group consolidate financial statementsoperating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease receipt noncancellable lease millions chf present value gross investment lease minimum lease receipt year year year total unearned finance income na na unguaranteed residual value na na net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income operating lease future minimum lease receipt noncancellable lease millions chf year year year total minimum receipt capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc roche group note roche group consolidate financial statement roche finance report goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical chugai total pharmaceutical division diabetes care professional diagnostic molecular diagnostic apply science tissue diagnostic strategic goodwill hold divisional level allocate business area total diagnostic division impairment charge impairment charge total million swiss franc record related goodwill impairment charge million swiss franc record tissue diagnostic business area diagnostic division impairment base late business plan prepare second half main factor leading impairment reduce revenue expectation follow recent change college american pathologist guideline use negative reagent control immunohistochemistry testing reduce volume change reduce reimbursement laboratory april group announce reorganisation apply science business area note goodwill impairment charge million swiss franc incur writeoff goodwill life sciences acquisition innovatis acquisition apply science business area goodwill impairment charge million swiss franc incur writeoff goodwill nimblegen acquisition note roche finance report roche group note roche group consolidate financial statementsimpairment testing pharmaceutical division division subdivision cashgenerate unit test goodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection roche pharmaceutical impairment testing base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation business plan project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation business plan project year tissue diagnostic business area project year reflect longterm nature business valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai decrease publicly quote share price tissue diagnostic business area result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable december key assumption change result goodwill impairment million swiss franc tissue diagnostic business area december roche group note roche group consolidate financial statement roche finance report intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination addition transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group roche finance report roche group note roche group consolidated financial statementssignificant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use tanox acquisition roche pharmaceutical year corangeboehringer mannheim acquisition diagnostic year ventana acquisition diagnostic year product intangible available use ventana acquisition diagnostic na cmi acquisition diagnostic na classification amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment roche group note roche group consolidate financial statement roche finance report impairment charge pharmaceutical division impairment charge total million swiss franc record related portfolio reassessment hepatitis c virus hcv franchise million swiss franc asset concern amortise write recoverable value million swiss franc portfolio reassessment cardiovascular metabolic disease franchise million swiss franc asset concern amortise fully write decision stop collaboration project alliance partner million swiss franc asset concern amortise fully write decision stop development compound alliance partner million swiss franc asset concern amortise fully write diagnostic division impairment charge total million swiss franc record apply science business area reorganisation note asset concern amortise fully write impairment charge pharmaceutical division impairment charge total million swiss franc record relate clinical datum assessment project acquire marcadia acquisition million swiss franc global restructuring initiative million swiss franc mainly relate termination dalcetrapib trial note portfolio prioritisation decision million swiss franc mainly relate return monoclonal antibody rg antiplgf mab alliance partners clinical datum assessment collaboration project alliance partner million swiss franc decision stop development compound alliance partner million swiss franc diagnostic division impairment charge total million swiss franc record mainly relate apply science business area restructuring note potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure undiscounted risk adjust meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total roche finance report roche group note roche group consolidate financial statement inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total billion swiss franc billion swiss franc inventory write down year result expense million swiss franc million swiss franc account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance total account receivable allowance doubtful account movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt reversal credit marketing distribution total million swiss franc expense million swiss franc roche group note roche group consolidate financial statement roche finance report marketable security marketable security millions chf availableforsale financial asset equity security debt security money market instrument time account month investment total marketable security marketable security hold fund management purpose primarily denominate swiss franc dollar euro money market instrument contract mature year december debt security contract maturity million chf year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent roche finance report roche group note roche group consolidate financial statement noncurrent asset noncurrent asset million chf availableforsale investment hold fair value availableforsale investment hold cost loan receivable longterm trade receivable restrict cash receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset availableforsale investment mainly equity investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably current asset current asset millions chf accrue interest income derivative financial instrument restrict cash receivables total financial current asset prepay expense tax recoverable asset total nonfinancial current asset total current asset receivables mainly relate royalty licensing income receivables roche group note roche group consolidate financial statement roche finance report account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability mainly relate accrue longterm employee benefit current liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue chargeback allowance accrue royalty commission accrue liability total current liability roche finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company contingent consideration currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company contingent consideration currency translation effect december current noncurrent december expect outflow resource year year year year december legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict legal expense total million swiss franc million swiss franc reflect recent development legal matter detail major legal case outstanding disclose roche group note roche group consolidate financial statement roche finance report environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate closure site nutley new jersey estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago increase million swiss franc estimate remediation cost landfill site near grenzach base late remediation plan submit local authority approval result environmental investigation nutley show expect cost remediation lower originally expect accordingly environmental provision reduce million swiss franc restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter significant provision relate restructure research development activity pharmaceutical division mainly relate closure site nutley new jersey restructuring diabete care apply science business diagnostic division employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past performance provision timing cash outflow nature uncertain good estimate show table provision million chf sale return contingent consideration item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note roche finance report roche group note roche group consolidated financial statementspharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action united states relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder december hlr defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use accutane action allege ibd result accutane use hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation district court middle district florida tampa division july district court grant summary judgment favour hlr federal ibd case proceed august ruling affirm court appeal eleventh circuit plaintiff appeal multiple recently file matter remain pende action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess total compensatory damage total million dollar rule favour hlr case case originally rule favour plaintiff superior court hlr process appeal case million dollar case schedule retrial january million dollar posttrial briefing ongoing case million dollar case verdict reverse favour hlr million dollar additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim rituxan arbitration october genentech biogen idec inc file complaint california sanofiaventis deutschland gmbh sanofi sanofiaventis llc sanofiaventis inc seek declaratory judgment certain genentech product include rituxan infringe sanofis patent nos patent invalid sanofi allege rituxan genentech product infringe certain claim patent march district court rule matter law genentech biogen idec infringe assert patent claim sanofi appeal court noninfringement rule appellate court affirm district court judgment patent infringement addition october sanofi affiliate hoechst gmbh file icc international court arbitration paris request arbitration genentech relate terminate patentlicense agreement hoechst predecessor genentech pertain abovementione patent relate patent outside hoechst seek payment patentlicense royalty sale certain genentech product include rituxan damage breach contract relief arbitral award september february arbitrator find genentech liable hoechst patentlicense royalty rituxan award royalty interest hoechst seek february group record royalty expense million swiss franc net assume reimbursement portion group obligation copromotion partner corresponding accrue liability december accrue liability million swiss franc hoechst initiate proceeding france germany seek enforce arbitral awards october genentech pay award royalty interest hoechst protest genentech seek annulment arbitral award proceeding initiate court appeal paris hearing proceeding schedule june outcome matter determine time roche group note roche group consolidate financial statement roche finance report average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey discovery currently pende case hlr rli vigorously defend matter outcome matter determined time pdl litigation august pdl biopharma pdl file complaint nevada genentech seek judicial declaration concern genentech obligation pay royalty certain exus sale herceptin avastin xolair lucentis agreement party september pdl file amend complaint assert additional claim genentech include breach contract breach imply covenant good faith fair dealing pdl assert new claim roche novartis intentional interference contractual relation addition declaratory relief pdl seek monetary damage include compensatory liquidate damage november genentech roche file motion dismiss failure state claim roche file additional motion dismiss lack personal jurisdiction july court deny motion pdl settle claim novartis addition litigation pdl conduct royalty audit relate sale avastin herceptin lucentis xolair raptiva year final audit report indicate pdls interpretation certain contract term genentech owe pdl additional royalty audit period interpretation genentech owe additional royalty year subsequent audit period group dispute pdls interpretation relevant contract term believe additional royalty owe june pdl file demand arbitration relate audit claim american arbitration association party stay arbitration proceeding nevada litigation engage discussion determine settlement certain issue possible gsk litigation september glaxosmithkline llc gsk genentech file patent lawsuit delaware california respectively lawsuit concern gsk patent nos gsk assert claim genentech allege infringement patent herceptin lucentis seek compensatory damage lawsuit genentech seek judicial declaration noninfringement invalidity patent june party agree dismiss california action prejudice consolidate case proceed delaware august delaware court issue claim construction order construe term patent trial schedule june outcome matter determine time boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court action bring court queen bench province saskatchewan canada personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time roche finance report roche group note roche group consolidated financial statementsema investigation october european medicines agency ema announce start infringement procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine november ema announce result pharmacovigilance risk assessment committee assessment roche medicine ema find impact benefitrisk balance roche medicine confirm benefitrisk profile base available safety information ema health authority confirm medicine remain authorised change treatment advice patient healthcare professional corrective preventative action result inspection implement reinspection authority november lead certain finding roche address ema infringement procedure ongoing ema expect issue report eu commission april late outcome investigation determine time diagnostic legal case marsh supermarket litigation july marsh supermarkets inc marsh file breach contract suit roche diagnostic operation inc rdo lawsuit relate termination sublease agreement building rdo december hamilton superior court judge award marsh million dollar provide april court appeal indiana upheld judgment october indiana supreme court decline hear appeal roche rdo pay final award damage interest million dollars marsh matter conclude debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt net gain loss redemption repurchase bond note amortisation debt discount business combination net foreign currency transaction gain loss currency translation effect december bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche group note roche group consolidate financial statement roche finance report bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note fix rate note march principal billion dollar isin usual usaq note march principal billion dollar outstanding billion dollars isin usuam usas note march principal billion dollars isin usuan usau na european medium term note programme fix rate note march principal billion euro isin xs note march principal billion pound sterle outstanding billion pound sterling isin xs note march principal billion euro outstanding billion euro isin xs note june principal billion euro isin xs na note march principal billion euro isin xs note august principal million pound sterle outstanding million pound sterling isin xs na swiss franc bond float rate note september principal billion swiss franc isin ch na swiss franc bond fix rate bond march principal billion swiss franc isin ch bond march principal billion swiss franc isin ch na bond september principal billion swiss franc isin ch bond september principal billion swiss franc isin ch na genentech senior note senior note july principal billion dollar isin usag na senior note july principal million dollar isin usac na total bond note roche finance report roche group note roche group consolidated financial statementsbond note maturity million chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note group issue bond note issuance bond note group raise net proceed approximately billion swiss franc series debt offering newly issue debt senior unsecured guarantee roche holding ltd redemption repurchase bond note redemption eurodenominate note date march group redeem fix rate note principal billion euro cash outflow million swiss franc plus accrued interest gain loss record redemption effective interest rate note redemption dollardenominated note december group resolve exercise option redemption entire outstanding dollardenominated fix rate note march march group redeem remain outstanding principal billion dollar equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrue interest additional million swiss franc loss record redemption effective interest rate note partial redemption dollardenominated note june group resolve exercise option early partial redemption dollardenominate fix rate note march august group redeem outstanding principal million dollar equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrue interest million swiss franc loss record redemption effective interest rate note redemption swiss francdenominate bond date september group redeem float rate bond principal billion swiss franc cash outflow million swiss franc plus accrued interest gain loss record redemption effective interest rate note roche group note roche group consolidate financial statement roche finance report early redemption dollardenominated note december group resolve exercise option early partial redemption dollardenominate fix rate note march group redeem outstanding principal billion dollar march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal treasury rate determine independent investment banker business day precede redemption cash outflow approximately million dollar plus accrue interest expect redemption group revise carrying value note account change amount timing estimate cash flow revise carrying value note december million dollar million swiss franc increase carry value million dollar million swiss franc record financing cost note loss redemption effective interest rate note redemption repurchase bond note group redeem billion swiss franc bond date complete tender offer repurchase billion euro note billion swiss franc exercise option early redemption billion dollar note march cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf european medium term note programme eurodenominate note swiss francdenominate bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf european medium term note programme eurodenominate note dollardenominate note swiss francdenominate bond total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro available backstop line maturity note program exceed day date issuance december unsecured commercial paper note principal million dollar average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december roche finance report roche group note roche group consolidated financial statementsamount bank financial institution amount denominate currency notably chinese renminbi argentine peso average interest rate amount outstanding million swiss franc december year equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity december disclose note reserve december december restate follow accounting policy change adopt reconciliation previously publish reserve provide note entire transfer income statement report financial income expense roche group note roche group consolidate financial statement roche finance report change equity attributable roche shareholder millions chf reserve share retain fair capital earning value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity december entire transfer income statement report financial income expense genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statementsshare capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security derivative instrument total roche group note roche group consolidate financial statement roche finance report equity instrument record equity original purchase cost detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting strike price market value equity security million maturity chf chf billion share nonvoting equity securities jan derivative instrument feb total equity instrument hold group potential conversion obligation arise group equity compensation plan note derivative instrument mainly consist option exercisable time maturity reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs roche finance report roche group note roche group consolidate financial statementsfinancial information chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche roche group note roche group consolidate financial statement roche finance report rest world umbrella right agreement sign roche right refusal development marketing chugais development compound market outside japan exclude south korea chugai decide require partner activity agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest disclose note noncontrolle interest year end december restate follow accounting policy change adopt reconciliation previously publish noncontrolle interest provide note roche finance report roche group note roche group consolidate financial statement employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit pension postemployment benefit disclose note follow implementation ias revise group amend accounting policy respect pension postemployment benefit restate related comparative disclosure group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group long term financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan united states notably roche k saving plan roche group note roche group consolidate financial statement roche finance report define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation semiannual update prepare accordance requirement ias use group financial statement group major define benefit plan locate switzerland germany total account group define benefit obligation pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility past service cost include million swiss franc income record respect change group pension plan switzerland change represent adoption low conversion rate determine annuity normal retirement age pension plan united states group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan include separate plan originate nutley palo alto indianapoli site small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan payment group million dollar million dollar underfunding normally remedie additional company contribution pension plan offer defer vested member settle define benefit obligation lump sum payment total lump sum payment define benefit asset million dollar million swiss franc settle obligation million dollar million swiss franc lead gain million dollar million swiss franc include settlement gain past service cost include million swiss franc income record respect curtailment define benefit plan arise primarily reorganisation pharmaceutical division research development organisation involve closure site nutley new jersey pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contributionbase minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan past service cost include million swiss franc income record respect change group german pension plan change represent adoption increase normal retirement age roche finance report roche group note roche group consolidated financial statementspension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs financial statement uk pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan past service cost include million swiss franc income record respect change group uk pension plan reflect change indexation pension increase consumer price index instead previously retail price index postemployment benefit opeb plan represent approximately group define benefit obligation consist postretirement healthcare life insurance scheme mainly plan mainly unfunde contributory employee group reimburse retire employee directly financial resource group major define benefit opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund opeb plan define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level fair value plan asset increase favourable market condition high discount rate compare change pension plan switzerland germany uk describe result decrease overall define benefit obligation result ifrs fund status fund define benefit plan improve reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act roche group note roche group consolidate financial statement roche finance report define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liability plan asset responsibility investment strategy fund plan senior governance body board trustee assetliability study perform regularly major pension plan study examine obligation postretirement benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use annuity longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset gain million swiss franc gain million swiss franc recognition pension asset limit present value economic benefit available refund plan reduction future contribution plan roche finance report roche group note roche group consolidated financial statementsdefine benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset remeasurement plan asset currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement past service income cost administration cost december define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property mainly private commercial property fund quote market price level fair value hierarchy directly hold property investment level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity risk management purpose mainly quote market price level fair value hierarchy include fair value plan asset group share nonvoting security fair value million swiss franc million swiss franc debt instrument issue group fair value million swiss franc million swiss franc swiss pension plan purchase million roche share group million swiss franc roche group note roche group consolidate financial statement roche finance report define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee uk join group define contribution plan new employee germany join contributionbase plan minimum guarantee define benefit pension plan switzerland final benefit contribution base minimum guarantee remain open new employee result proportion define benefit obligation relate closed plan expect decrease future define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year roche finance report roche group note roche group consolidated financial statementsactuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour group company average life expectancy assume individual age follow define benefit plan average life expectancy major scheme year male female country mortality table switzerland bvg generational table united states rp project germany heubeck table g financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase generally link expected inflation rate expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development roche group note roche group consolidate financial statement roche finance report sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf year increase life expectancy discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution relate define benefit plan benefit pay unfunded plan estimate approximately million swiss franc relate german define benefit plan roche finance report roche group note roche group consolidate financial statement equity compensation plan group operate equity compensation plan include separate plan chugai ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai stock acquisition right total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai stock acquisition right exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note roche group note roche group consolidate financial statement roche finance report equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date ssar plan regulation restate amend effective january refer roche ssar plan roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance condition currently performance condition outstanding rsus december rsu plan regulation restate amend effective january refer roche rsu plan roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche finance report roche group note roche group consolidated financial statementsroche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equity settle award programme currently operate annual threeyear cycle roche performance share plan regulation restate amend effective january refer roche psp plan roche psp plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero nonvoting equity security value adjustment depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan million swiss franc million swiss franc roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date roche option plan regulation restate amend effective january refer roche option plan option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment roche group note roche group consolidate financial statement roche finance report roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total weighted average share price roche nonvoting equity security year swiss franc swiss franc bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date chugai stock acquisition right chugai stock acquisition right programme total fair value right issue equivalent million swiss franc million swiss franc right issue employee director chugai right nontradable equitysettle award tenyear duration vest year right entitle holder purchase chugai share specify exercise price addition right issue director chugai thirtyyear duration vest holder retirement director chugai right entitle holder purchase chugai share exercise price japanese yen roche finance report roche group note roche group consolidate financial statementsfair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche stocksettle roche stock appreciation roche restrict performance share roche option right stock unit plan plan plan progressively cliff vest cliff vest progressively vest period year year year year contractual life year na na year number grant year weight average fair value chf model binomial market price monte carlo b binomial input option pricing model share price grant date chf exercise price chf expect volatility c na na expect dividend yield na na early exercise factor na na expect exit rate na na fair value roche rsus equivalent share price date grant b input parameter covariance matrix roche individual company peer group base threeyear history risk free rate minus valuation take account define rank performance structure determine payout plan c volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf roche group note roche group consolidate financial statement roche finance report dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf disclose note earning share nonvoting equity security year end december restate follow accounting policy change adopt reconciliation previously publish earning share nonvoting equity security provide note statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown adjustment cash generate operation disclose note net income nonoperate income expense year end december restate follow accounting policy change adopt reconciliation previously publish net income nonoperate income expense provide note roche finance report roche group note roche group consolidated financial statementscash flow investing activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder dividend withholding tax total significant noncash transaction significant noncash transaction risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie roche group note roche group consolidate financial statement roche finance report financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset account receivable december group trade receivables billion swiss franc billion swiss franc subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount december group combine trade receivable balance national wholesale distributor amerisourcebergen corp mckesson corp cardinal health inc equivalent billion swiss franc represent group consolidate trade receivable billion swiss franc represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold trade receivables financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable billion swiss franc billion swiss franc public customer country december trade receivables italy greece portugal decrease improved collection spain remain stable compare group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total roche finance report roche group note roche group consolidated financial statementsthe age account receivable impair show table age account receivable impair millions chf overdue impair overdue month overdue month overdue month overdue month overdue year total account receivable cash marketable security december group cash marketable security billion swiss franc billion swiss franc subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution rate analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange unrated total master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss availableforsale financial asset amount million swiss franc million swiss franc roche group note roche group consolidate financial statement roche finance report liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total billion swiss franc billion swiss franc billion swiss franc serve backstop line commercial paper programme remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carry value total year year year year year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread roche finance report roche group note roche group consolidated financial statementsmarket risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component increase mainly gradual increase longterm interest rate major economy foreign exchange component decrease favourable exposure mix price component arise mainly movement equity security price remain largely stable foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc eurodenominate float rate financial instrument primary objective group interest rate management protect net interest result group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure interest rate hedging group enter follow interest rate hedge contract interest rate swap contract combine notional principal billion dollar swap fix interest rate effective float interest rate month usdlibor plus average spread maturity swap march interest rate swap contract combine notional principal million swiss franc swap fix interest rate effective float interest rate month chflibor plus average spread maturity swap september price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment roche group note roche group consolidate financial statement roche finance report capital management group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation disclose note total equity december december restate follow accounting policy change adopt reconciliation previously publish total equity provide note group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management roche finance report roche group note roche group consolidate financial statementsfinancial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf fair value loan total available hedge fair value financial carry forsale instrument designate receivables liability value fair value year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability fair value bond note calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche group note roche group consolidate financial statement roche finance report fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date availableforsale investment valuation model derive recently publish observable financial price group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year roche finance report roche group note roche group consolidate financial statementslevel fair value detail determination level fair value measurement transfer level fair value hierarchy set contingent consideration arrangement millions chf january arise business combination total unrealised gain loss include income statement unused amount reverse additional create discount unwind total gain loss include comprehensive income currency translation effect transfer level utilise december contingent consideration arrangement group party certain contingent consideration arrangement arise business combination arrangement fair value determine consider expect payment discount present value riskadjusted discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate high riskadjuste discount rate low december payment contingent consideration arrangement million swiss franc derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net roche group note roche group consolidate financial statement roche finance report collateral arrangement fair value currency swap increase mainly strong euro compare dollar result cash deliver group counterpartie movement cash collateral receivable accrue liability millions chf january net cash deliver group december hedge accounting december group follow cash flow hedge fair value hedge designate qualifying hedge relationship cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euros sterling december instrument record fair value asset million swiss franc asset million swiss franc ineffective portion group enter foreign exchange forward contract hedge foreign translation exposure euro remain foreign exchange forward contract mature result loss million swiss franc record income statement december instrument record fair value liabilitie million swiss franc chugai enter foreign exchange forward contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset million swiss franc asset million swiss franc ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow roche finance report roche group note roche group consolidated financial statementsthe change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument december instrument record fair value liabilitie million swiss franc fair value asset million swiss franc asset million swiss franc loss million swiss franc record interest rate swap loss million swiss franc fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record fair value liabilitie million swiss franc liability million swiss franc loss million swiss franc record forward contract loss million swiss franc result forward contract offset change fair value hedge equity investment net investment hedge group net investment hedge relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalski hoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool mr andr hoffmann dr andreas oeri members board director roche holding ltd mr hoffmann receive remuneration total swiss franc swiss francs dr oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel total remuneration key management personnel million swiss franc million swiss franc million swiss franc member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee total remuneration board director exclude chairman chief executive officer total million swiss franc million swiss franc million swiss franc roche group note roche group consolidate financial statement roche finance report chairman board director member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee mr diggelmann dr hippe include table calendar year join cec similarly members corporate executive committee retire way year dr soriot dr hunziker include calendar year leave cec remuneration chairman board director member corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plan retirement awards employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include financial statement roche holding ltd basel page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration chairman board director member corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration chairman board director member corporate executive committee swiss legal basis chairman board director member corporate executive committee roche finance report roche group note roche group consolidated financial statementsbonus stock award chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date equity compensation plan chairman board director member corporate executive committee receive equity compensation show follow table number right option award grant corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan contribution pay chairman board director corporate executive committee millions chf roche connect transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc million swiss franc define benefit plan transaction group define benefit plan employee group describe note subsidiary associate list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy roche group note roche group consolidate financial statement roche finance report nonliste company share capital equity interest country company city millions algeria roche algrie spa bab ezzouar dzd argentina productos roche sa qumica e industrial buenos aire ars vanguardia en productos farmacuticos buenos aire ars vanprofarma sa australia roche diagnostics australia pty limited castle hill aud roche product pty limited dee aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk byr belgium nv roche sa brussels eur roche diagnostic belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican republic producto roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc egypt ropharm limited cairo egp estonia roche eesti tallinn eur finland roche diagnostic oy espoo eur roche oy espoo eur france institut roche de recherche et mdecine translationnelle sas boulognebillancourt eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel roche finance report roche group note roche group consolidate financial statementsshare capital equity interest country company city millions germany galenus mannheim gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories ag heidelberg eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen dem swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche product ghana limit accra ghs greece roche hellas sa athens eur roche diagnostic hellas sa athens eur guatemala producto roche guatemala sa guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr iran roche par co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy roche diagnostic spa milan eur roche spa milan eur ivory coast roche cte divoire sarl abidjan xof japan roche diagnostic kk tokyo jpy kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga lvl lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius lit macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr syntex pharmaceutical sdn bhd kuala lumpur myr mauritius roche product mauritius limited quatre borne mur mexico producto roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn moldova roche product limit srl chisinau mdl morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherland roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama producto roche panam sa panama city pab producto roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd roche group note roche group consolidate financial statement roche finance report share capital equity interest country company city millions peru producto roche qumica farmacutica sa lima pen philippine roche philippines inc taguig city php poland roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche product proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostic sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sri lanka roche product colombo private limited colombo lkr sweden roche ab stockholm sek roche diagnostic scandinavia ab bromma sek switzerland f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ltd burgdorf chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diagnostic middle east fzco dubai ae roche middle east fzco dubai ae united kingdom pirame limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp roche finance report roche group note roche group consolidate financial statementsshare capital equity interest country company city millions united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bioveris corporation indianapoli usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd igen international inc pleasanton usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche health solution inc fisher usd roche holdings inc south san francisco usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche tcrc inc new york usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela producto roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital local currency unit roche group note roche group consolidate financial statement roche finance report significant accounting policy consolidation policy subsidiary company include structured entity group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average year end exchange rate take directly comprehensive income roche finance report roche group note roche group consolidated financial statementsrevenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform single transaction split separately identifiable component reflect substance transaction necessary conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase iv cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset roche group note roche group consolidate financial statement roche finance report license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment roche finance report roche group note roche group consolidated financial statementspension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee finance lease exist substantially risk reward ownership transfer group finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period lease group lessor certain asset mainly diagnostic instrument lease party finance operating lease arrangement finance lease asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method operating lease asset report property plant equipment lease income operating lease recognise lease term straightline basis roche group note roche group consolidate financial statement roche finance report business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value available use intangible asset amortise straightline basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciationamortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost sell value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense roche finance report roche group note roche group consolidate financial statementsaccount receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise marketing distribution expenses trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available financial instrument financial instrument classify follow category disclose note availableforsale nonderivative financial asset designate classified financial asset category availableforsale asset initially record subsequently carry fair value change fair value record comprehensive income impairment interest foreign exchange component investment derecognise cumulative gain loss equity reclassify financial income expense availableforsale asset mainly comprise marketable security fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense fair value designate nonderivative financial instrument designate fair value profit loss initial recognition designate fair value instrument initially record subsequently carry fair value change fair value record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result roche group note roche group consolidate financial statement roche finance report loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest rate method impairment loss loan receivables mainly comprise account receivable cash cash equivalent financial liability nonderivative financial liability financial liability initially record fair value subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire impairment financial asset financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity security market value original cost market value original cost sustain sixmonth period consider impaired financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income roche finance report roche group note roche group consolidate financial statementsfair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan change accounting policy group adopt follow new standard amendment standard include consequential amendment standard date initial application january ias revise employee benefit ifrs consolidated financial statement ifrs joint arrangement ifrs disclosure interest entity ifrs fair value measurement presentation item comprehensive income amendment ias annual improvement ifrs cycle cycle cycle exception revision ias material impact group overall result financial position nature effect change relevant group financial statement explain roche group note roche group consolidate financial statement roche finance report pension postemployment benefit result ia revise group amend accounting policy respect basis determine income expense relate define benefit plan restate result retrospectively main change follow revise standard eliminate option defer recognition actuarial gain loss define benefit plan know corridor method group apply option use option recognise gain loss directly comprehensive income option currently apply group requirement revise standard change impact group financial statement net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment previously expect income plan asset base estimate longterm rate underlie asset plan impact restate result reduction net financial income million swiss franc year end december ongoing impact expect similar magnitude impact group operate income net asset change past service cost recognise immediately income statement period plan amendment previously past service cost portion relate unvested benefit defer balance sheet progressively release impact change increase group net asset million swiss franc december increase million swiss franc december follow revision ias disclose group presentational change income statement rename financial income financial income expense move caption financing cost reconciliation result publish previously previous accounting policy restate amount report comparative revised accounting policy present restate roche group consolidate income statement million chf year end december application originally ias publish revise restate operating profit associate financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group note roche group consolidated financial statementsrestate roche group consolidated statement comprehensive income million chf year end december application originally ia publish revise restate net income recognise income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest restate roche group consolidate balance sheet select item millions chf december december application application originally ia originally ias publish revise restate publish revise restate defer tax asset define benefit plan asset defer tax liability define benefit plan liability net asset net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity consolidation policy result ifrs group amend accounting policy determine control consequently consolidate investee group control entity group expose right variable return involvement entity ability affect return power entity change impact group financial statement fair value ifrs establishe single framework measure fair value make disclosure fair value measurement measurement require permit ifrss ifrs unify definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date replace expand disclosure requirement fair value measurement ifrss include ifrs financial instrument disclosure accordance transitional provision ifrs group apply new fair value measurement guidance prospectively provide comparative information new disclosure change impact measurement group asset liabilitie roche group note roche group consolidate financial statement roche finance report presentation item comprehensive income result amendment ias group modify presentation item comprehensive income consolidate statement comprehensive income present separately item reclassified income statement future comparative information restate change change impact group overall result financial position future new revise standard group currently assess potential impact new revise standard interpretation effective january base analysis date group anticipate material impact group overall result financial position roche finance report roche group note roche group consolidate financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework version issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set page franz b humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial report roche finance report report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation fair presentation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation fair presentation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgement include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation fair presentation consolidate financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche group report statutory auditor consolidated financial statement roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ag ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche group report independent auditor internal control financial report roche finance report multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income equity attributable roche shareholder research development sale current ratio equity noncontrolle interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard dividend propose board director apply retrospectively roche group multiyear overview supplementary information roche finance report sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationaddition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information base members eu december comparative information restate include new eu member fiveyear period roche group multiyear overview supplementary information roche finance report supplementary core result ep information group basic diluted earning share give note annual financial statement allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental expense financial review exclude global issue outside healthcare sector group control currently exclude material onetime treasury item major debt restructuring currently exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report roche group multiyear overview supplementary informationcore result reconciliation million chf alliance normali global intangible business legal pension sation restruc amorti intangible combi environ plan ecp tax ifrs ture sation impairment nation mental settlement benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal pension sation restruc amorti intangible combi environ plan ecp tax ifrs ture sation impairment nation mental settlement benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest disclose note roche group annual financial statement core result year end december restate follow accounting policy change adopt adjustment publish ifrs result core result roche group multiyear overview supplementary information roche finance report divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore eps basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share diluted chf disclose note roche group annual financial statement earning share year end december restate follow accounting policy change adopt result core earning share year end december restate roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale group refine calculation free cash flow exclude impact employee stock option line peer group result operate profit cash adjustment year end december restate exclude net cash flow equitysettle compensation plan result increase million swiss franc group operate profit cash adjustment year end december divisional impact increase million swiss franc pharmaceutical million swiss franc diagnostic million swiss franc corporate roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset disclose note roche group annual financial statement taxation treasury net asset december restate follow accounting policy change adopt roche group multiyear overview supplementary information roche finance report r oche securities price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr sp index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate change ratio adr effective january change ratio adr effective january roche finance report roche group roche securitiesnumber share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend c stock price share b open high low yearend stock price nonvoting equity security genussschein b open high low yearend earning basic diluted core earning basic diluted equity attributable roche shareholder share nonvoting equity security restate follow accounting policy change adopt disclose note roche group annual financial statement information restate change accounting policy market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director roche group roche security roche finance report ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypk roche finance report roche group roche securitiesroche holding ltd basel financial statement note financial statement summary significant accounting policy r isk management e quity board executive remuneration contingent liability board executive shareholding ignificant shareholder appropriation available earning report statutory auditor financial statement financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit taxis tax net income roche finance report roche holding ltd basel financial statementsbalance sheet millions chf december december noncurrent asset participation longterm loan group company total noncurrent asset current asset account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine pm pm legal reserve general legal reserve reserve equity instruments free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company liabilitie total current liability total liability total equity liability pm pro memoria nonvoting equity security nominal value roche holding ltd basel financial statement roche finance report note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel prepare accordance provision swiss law participation major participation company list note roche group annual financial statement valuation method translation foreign currency marketable security equity instrument report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate equity instrument company purchase million roche share purchase price swiss franc share sell share average sale price swiss franc share december remain roche share net book value million swiss franc include marketable security roche finance report roche holding ltd basel notes financial statementsmovement recognise amount million chf share legal free special available total capital reserve reserve reserve earnings equity january net income dividend december net income dividend transfer free reserve december net income dividend reserve equity instrument december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc billion swiss franc describe note roche group annual financial statement page significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist ms vera michalski hoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis ltd basel include affiliate thereof participation roche holding ltd basel note financial statement roche finance report risk management detailed disclosure risk management require swiss law include note roche group annual financial statement page board executive remuneration board director member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration member board director thousands chf b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink c franz julius levinson oeri schwan b p r voser b weder di mauro total annual general meeting march prof gehrig mr de vink stand reelection b annual general meeting march dr schwan elect new member board director remuneration include table member corporate executive committee remuneration dr levinson include payment consult work board membership genentech total thousand swiss franc thousand swiss franc chairman board directors dr franz b humer receive remuneration show table remuneration chairman board director thousands chf annual salary include cashsettled bonus bonus stock award pension postemployment benefit equity compensation plan employee benefit total remuneration receive social security cost total annual shareholder meeting march propose dr christoph franz elect chairman board director succeed dr humer standing reelection roche finance report roche holding ltd basel notes financial statementscorporate executive committee member corporate executive committee cec roche holding ltd receive remuneration indirect benefit participate certain equity compensation plan show table group ceo dr severin schwan member cec high total remuneration remuneration disclose new member cec mr diggelmann dr hippe include calendar year join cec similarly member cec retire way year dr soriot dr hunziker include calendar year leave cec remuneration member corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary include cashsettled bonus bonus stock award pension postemployment benefit equity compensation plan retirement awards employee benefit total remuneration receive social security cost total bonus stock award chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april total fair value employee thousand swiss franc fair value award employee calculate take account period block year year number award fair value award calculate grant date employer contribution social security scheme pension plan group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee equity compensation plan chairman board director member corporate executive committee participate certain equity compensation plan describe term vest condition award disclose note roche group annual financial statement fair value roche group annual financial statement represent cost company grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition purpose remuneration disclosure value calculate base fair value employee receive take account preliminary assessment complete performance condition chairman board director member corporate executive committee eligible participate roche connect programme enable employee regular deduction salary purchase nonvoting equity security group contribute programme allow employee purchase nonvoting equity security discount usually member corporate executive committee grant stocksettle stock appreciation right ssar individual award relate show table fair value award employee thousand swiss franc calculate trinomial model american option roche holding ltd basel note financial statement roche finance report member corporate executive committee grant restrict stock unit rsus individual award relate show table fair value award employee thousand swiss franc calculate base average market nonvoting equity security price day period prior grant date member corporate executive committee member senior management participate roche performance share plan psp group overlapping threeyear psp target award threeyear cycle define begin cycle award consider form employee remuneration equal annual amount threeyear cycle award result zero nonvoting equity security depend achievement performance target discretion board director individual award relate show table number award calculate follow psp end cycle performance target achieve accordingly participant receive originally target nonvoting equity security psp nonvoting equity security award psp nonvoting equity security award result allocation multiply nonvoting equity security price december swiss franc fair value remuneration receive employee remuneration equity compensation plans schwan cec members total cec fair value fair value fair value number chf thousands number chf thousands number chf thousand roche connect employer contribution ssar award rsus award psp psp psp psp fair value total fair value employee benefit include tax advisory cost incidental benefit transaction member corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc million swiss franc roche finance report roche holding ltd basel note financial statement board executive shareholdings board director director mr andr hoffmann dr andreas oeri member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine f b humer b b gehrig na na hoffmann c p baschera j bell p bulcke w burns b l j r de vink na na c franz julius levinson oeri c schwan na na b e p r voser b weder di mauro total include share hold shareholder group pool voting right b equity compensation award roche option plan ssar rsus roche performance share plan c mr hoffmann dr oeri hold ubs longshort certificate roche share ro versus roche nonvoting equity security genussscheine rog mr de vink hold roche american depositary receipt adr e dr schwan appoint board director march shareholdings disclose table member corporate executive committee roche holding ltd basel note financial statement roche finance report corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi r diggelmann hippe g keller b oday total equity compensation award roche option plan ssar rsus roche performance share plan b close relative dr keller hold roche share roche share december chairman board director mr burns members corporate executive committee hold roche option plan award rop stocksettle stock appreciation right ssar show table award hold dr humer current chairman board director mr burns current member board director issue previous capacity member corporate executive committee term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include business report annual report page rop ssar award hold december year issue total schwan ayyoubi r diggelmann hippe g keller oday total cec f b humer w burn total strike price chf b expiry date mar mar feb feb feb jan b feb dr hippes awards strike price chf expire april b mr diggelmann awards strike price chf expire july roche finance report roche holding ltd basel notes financial statementsat december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report page business report annual report award result zero nonvoting equity security value adjustment depend achievement performance target discretion board director end cycle performance target achieve accordingly participant receive originally target nonvoting equity security total target number award outstanding performance cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi r diggelmann hippe g keller oday total cec allocation date feb feb december chairman board director mr burns members corporate executive committee time hold total stocksettle stock appreciation right outstanding total award grant roche performance share plan roche holding ltd basel note financial statement roche finance report appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche finance report roche holding ltd basel appropriation available earningsreport statutory auditor financial statement report statutory auditor financial statement annual general meeting roche holding ltd basel statutory auditor audit accompany financial statement roche holding ltd comprise income statement balance sheet note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgement include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation roche holding ltd basel report statutory auditor financial statement roche finance report report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article co article aoa circumstance incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ag ian starkey franois rouiller license audit expert license audit expert auditor charge basel january roche finance report roche holding ltd basel report statutory auditor financial statementspublishe cautionary statement forwardlooke f hoffmannla roche ltd statement basel switzerland annual report contain certain forwardlooking statement tel forwardlooke statement identi fie word fax believe expect anticipate project intend seek estimate future similar expression medium office discussion thing strategy goal plan group communication intention factor cause actual result differ basel switzerland materially future reflect forwardlooke tel statement contain annual report fax pricing product initiative competitor legislative regulatory development economic condition delay investor relation inability obtain regulatory approval bring product basel switzerland market fluctuation currency exchange rate general tel financial market condition uncertaintie discovery fax development marketing new product new use exist product include limitation negative result website clinical trial research project unexpected effect wwwrochecom pipeline market product increase government pricing pressure interruption production loss order publication inability obtain adequate protection intellectual tel property right litigation loss key executive fax employee adverse publicity news coverage email baselwebmasterrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark mention enjoy legal protection roche finance report publish german english case doubt difference interpretation english version shall prevail german text print nonchlorine bleach fsccertified paper roche annual report issue f hoffmannla roche ltd basel group communicationse roche finance report f hoffmannla roche ltd finance report basel switzerland trademark legally protect wwwrochecom